Sort
16,179 grants matching “malaria”
Immunological characterization of the P. vivax DBP
$653,630John Adams · University Of South Florida · R01 · FY2016 · AI
Pathogenic low affinity CD8 T cells in malaria
$653,615Tracey Jane Lamb · University Of Utah · R01 · FY2021 · AI
Pathogenic low affinity CD8 T cells in malaria
$653,615Tracey Jane Lamb · University Of Utah · R01 · FY2022 · AI
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
$653,475Micah A. Luftig · Duke University · R01 · FY2020 · CA
Targeting a New Therapy for Trypanosomatids
$653,390Dawn Marie Wetzel · Ut Southwestern Medical Center · R01 · FY2021 · AI
The effect of inflammation and damage to lymph node structures on durable protective immunity following vaccination
$653,365Timothy W Schacker · University Of Minnesota · U01 · FY2022 · AI
STRENGTHENING NATIONAL CAPACITY IN MALARIA AND OTHER INFECTIOUS DISEASE OPERATION
$653,225Don P Mathanga · University Of Malawi · U01 · FY2009 · CK
OWL MONKEY BREEDING AND RESEARCH RESOURCE (R24)
$653,159Christian R Abee · University Of Tx Md Anderson Can Ctr · R24 · FY2008 · RR
Genetic Variation and Evolution of Artemisinin Resistance
$653,119Dyann F Wirth · Harvard School Of Public Health · R01 · FY2016 · AI
Targeting Hsp90 in cryptococcal fungal pathogenesis
$653,100Leah Elizabeth Cowen · University Of Toronto · R01 · FY2024 · AI
Placental Colonization by Treponema Pallidum, Congenital Syphilis & Novel Vaccine
$653,081Nikhat Parveen · Rbhs-New Jersey Medical School · U01 · FY2018 · AI
Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance
$652,918John Adams · University Of South Florida · R01 · FY2024 · AI
Effector and regulatory T cell responses and protection from clinical malaria
$652,709Margaret E Feeney · University Of California, San Francisco · R01 · FY2016 · AI
Innate lymphocyte function in malaria
$652,466Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Effector and regulatory T cell responses and protection from clinical malaria
$652,349Margaret E Feeney · University Of California, San Francisco · R01 · FY2018 · AI
Defining the targets of broad intervention antimalarial agents
$652,347Elizabeth A Winzeler · University Of California, San Diego · R01 · FY2015 · AI
Hemolytic Complications in Babesia Infections
$652,219Cheryl Ann Lobo · New York Blood Center · P01 · FY2021 · HL
Hemolytic Complications in Babesia Infections
$652,219Cheryl Ann Lobo · New York Blood Center · P01 · FY2020 · HL
Development of therapeutic chemokine-based formulations
$651,880Bira Arya · National Institute On Aging · ZIA · FY2015 · AG
DRUG DEVELOPMENT AND CONSERVATION OF BIODIVERSITY IN WES
$651,600U.S. Walter Reed Army Inst Of Research · U01 · FY2000 · TW
Leveraging the Mosquito Holobiont to Suppress Disease and Advance Avian Conservation
$651,084Matthew Medeiros · University Of Hawaii · · FY2024 · BIO
Enhanced collaboration between US NIH and WHO on biomedical research
$651,079Hans Troedsson · World Health Organization · U01 · FY2014 · AI
The genetic basis of emerging multidrug resistance in Plasmodium falciparum African malaria
$650,983Sachel Mok · Columbia University Health Sciences · R01 · FY2025 · AI
NSF/BIO-UKRI/BBSRC: Exploring genetic and environmental factors shaping Wolbachia-Anopheles Interactions
$650,970Zhiyong Xi · Michigan State University · · FY2025 · BIO
Dityrosine Locked Prefusion F Protein: A Path To A Protective RSV Vaccine
$650,899Mark Yondola · Calder Biosciences, Inc. · R44 · FY2017 · AI